<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Noeding, Stefanie</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Interim Safety Analysis of nP in High-Risk Early Breast Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">Combination chemotherapy requires compromises in drug dosage and treatment intervals because of acute and cumulative toxicities. The sequential use of monotherapies, however, allows for the use of high doses of single agents and dose-dense treatment intervals, and such regimens have been very effective in cases of early breast cancer with high risk of recurrence. This article discusses data from the first interim safety analysis of the Study of Nab-Paclitaxel in High-Risk Early Breast Cancer [GAIN2; NCT01690702], demonstrating acceptable initial toxicity profiles.</style></abstract><number><style face="normal" font="default" size="100%">36</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>